


# Accepted Manuscript

Randomized controlled trials covering pharmaceutical care and medicines management: A systematic literature review

Zaheer Ud-Din Babar, Rozina Kousar, Ghulam Murtaza, Saira Azhar, Shujaat Ali Khan, Louise Curley



PII: S1551-7411(17)30473-4

DOI: [10.1016/j.sapharm.2017.06.008](https://doi.org/10.1016/j.sapharm.2017.06.008)

Reference: RSAP 927

To appear in: *Research in Social & Administrative Pharmacy*

Received Date: 7 May 2017

Revised Date: 12 June 2017

Accepted Date: 15 June 2017

Please cite this article as: Babar ZUD, Kousar R, Murtaza G, Azhar S, Khan SA, Curley L, Randomized controlled trials covering pharmaceutical care and medicines management: A systematic literature review, *Research in Social & Administrative Pharmacy* (2017), doi: 10.1016/j.sapharm.2017.06.008.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Randomized controlled trials covering pharmaceutical care and medicines management: A systematic literature review**

Zaheer Ud-Din Babar<sup>1,3</sup>, Rozina Kousar<sup>2</sup>, Ghulam Murtaza<sup>2</sup>, Saira Azhar<sup>2</sup>, Shujaat Ali Khan<sup>2</sup>, Louise Curley<sup>3</sup>

1. Department of Pharmacy, School of Applied Sciences University of Huddersfield, Huddersfield, HD1 3DH, United Kingdom

2. Department of Pharmacy, COMSATS Institute of Information Technology Abbottabad, Khyber Pakhtunkhwa, Pakistan

3. School of Pharmacy, University of Auckland, Private Mail Bag 92019, Auckland, New Zealand

Corresponding Author

Zaheer Ud-Din Babar Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, HD1 3DH, United Kingdom

Email: z.babar@hud.ac.uk

**Author Contributions**

Conceived and designed the experiments: ZB. Performed the experiments: ZB, RK, LC.

Analyzed the data: ZB, RK, GM, SA, SA, LC. Contributed reagents/materials/analysis tools:

LC. Wrote the paper: ZB, RK, LC.

**Acknowledgement**

No funds received for this project.

# 1 Randomized controlled trials of pharmaceutical care: A systematic review

## 2 Abstract

### 3 Objective

4 To review the effects of pharmaceutical care on hospitalizations, mortality and clinical outcomes in  
5 patients.

### 6 Methods

7 Systematic searches were conducted in MEDLINE, EMBASE and International Pharmaceutical Abstracts  
8 (IPA) databases to identify studies that were published between 2004 and January 2017. Studies  
9 included in this review were randomized controlled trials (RCTs) that spanned across both community and  
10 hospital settings. Using strict inclusion/exclusion criteria studies were included if they reported level 1 or 2  
11 outcomes in the hierarchy of outcome measure i.e. clinical and surrogate outcomes (e.g. blood pressure  
12 (BP) control, blood glucose level, cholesterol BMI). Each study was assessed for quality using the Jadad  
13 scoring system.

### 14 Results

15 Fifty-four RCTs were included in the present review. Forty-six of these studies ranked high quality  
16 according to the Jadad scoring system. Studies were categorized into their general condition groups.  
17 Interventions in patients with diabetes, depression, respiratory disorders, cardiovascular disorders,  
18 epilepsy, osteoporosis, and interventions in older adults were identified. In the majority of studies  
19 pharmaceutical care was found to lead to significant improvements in clinical outcomes and/or  
20 hospitalizations when compared to the non-intervention group. Some conditions had a large number of  
21 RCTs, for example for cardiovascular conditions and in diabetes. Statistically significant improvements  
22 were seen in the majority of the studies included for both of these conditions, with studies indicating  
23 positive clinical outcomes and/or hospitalizations rates. Within the cardiovascular condition, a subset of  
24 studies, focusing on cardiac heart failure and coronary heart disease, had more mixed results. In other  
25 conditions the number of RCTs conducted was small and the evidence did not show improvements after  
26 pharmaceutical care, i.e. in depression, osteoporosis, and epilepsy. The majority of interventions were

27 face to face interactions with patients, whilst a smaller number were conducted via the telephone and one  
28 via a web-based system. Patient education was a key component of most interventions, either verbal  
29 and/or written. Longitudinal data, post intervention cessation, was not collected in the majority of cases.

### 30 **Conclusions**

31 RCTs conducted to evaluate pharmaceutical care appear to be effective in improving patient short-term  
32 outcomes for a number of conditions including diabetes and cardiovascular conditions, however, other  
33 conditions such as depression are less well researched. Future research should attempt to evaluate the  
34 conditions where there is a lack of data, whether the positive effects of pharmaceutical care persist in  
35 patient populations after the interventions cease and what the long-term clinical outcomes would be of  
36 continued pharmaceutical care.

37

## 38 Introduction

39 Worldwide, the demands on primary health care services are growing, mainly due to an ageing  
40 population (1). The consequence of this is an increased strain on the primary health care workforce (3-6)  
41 and as a result, primary health care systems have evolved to encompass new services. In some  
42 countries, this has led to extended roles for community pharmacists (7, 8). The pharmacy profession is  
43 evolving worldwide, moving from the traditional role of the technical dispenser to be more patient-focused  
44 (9). The concept of pharmaceutical care was first conceived by Hepler and Strand and is defined as the  
45 responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a  
46 patient's quality of life (10). According to the concept of pharmaceutical care, the patient care process is  
47 comprised of the establishment of a therapeutic relationship, assessment of medication related problems,  
48 development of a care plan, evaluation and continuous follow-up (11). Pharmacists are responsible for  
49 the quality and effectiveness of pharmaceutical care for the benefit of patients to improve their health care  
50 outcomes (12).

51 Since its conception, various terms have been used to describe pharmaceutical care including medication  
52 review, medication management, clinical pharmacy services and cognitive services and all of these are  
53 defined by similar practices (13). According to some authors, pharmaceutical care is closely related to  
54 medicines management but includes the patient's perspective and pharmacists societal perspective (14).  
55 Pharmacists counsel patients with a focus on educating health management or drug related-problems  
56 (identification, resolution or prevention), they develop a care-plan for the individual patient and follow-up  
57 the pharmacotherapy (15).

58 Studies investigating the effects of pharmaceutical care on short and long term patient outcomes have  
59 been increasing over the past two decades; however there are mixed reports of whether the  
60 pharmaceutical care interventions are effective or not, with the intervention not always showing significant  
61 differences (16-18). Systematic reviews often focus on specific conditions for example, reviews have  
62 been conducted in patients with hypertension (19, 20) and in chronic kidney disease (21) and others  
63 have looked at pharmaceutical care in specific settings for example, in community pharmacy (22).

64 A previous systematic review of studies published between 1990 and 2003 was published in 2005. This  
65 review evaluated the effectiveness of pharmaceutical care across all conditions and concluded that the  
66 pharmaceutical care is effective in improving surrogate outcomes but less conclusive in other outcomes  
67 (23). Evidence of the effect of pharmaceutical care is constantly growing and regular systematic  
68 evaluation is important and relevant to healthcare. This current study included randomized controlled  
69 trials (RCTs) published since 2004 across all conditions, to evaluate the evidence of whether  
70 pharmaceutical care is effective for patients. The objective of this systematic review was to examine the  
71 effects of pharmaceutical care using patient outcomes (i.e. clinical and surrogate outcomes) in both the  
72 hospital and community setting..

73

## 74 **Methods**

### 75 **Search strategy**

76 The PRISMA guidelines for conducting the systematic review were followed. A systematic search of the  
77 literature was conducted to identify RCTs published in English language between 2004 and January 2017  
78 by using the electronic databases: Medline (Ovid SP), International Pharmaceutical Abstracts (IPA) and  
79 Embase. Our search included both mapped and unmapped terms, which are illustrated in figure 1. In  
80 addition, the following text words and MeSH/EMTREE terms were used to see if there were any  
81 additional relevant papers: The databases were searched for the following key terms in combination  
82 where appropriate: ("Pharmaceutical services"), ("Pharmaceutical care"), ("Medicine management"),  
83 ("Medicine therapy assessment"), ("Medicine therapy management"), ("Drug therapy management")  
84 ("Pharmacy services") ("Medication review"), ("Comprehensive medication review"), ("drug utilization  
85 management"), ("Drug therapy services"), ("Pharmacist intervention") and ("Patient centered care" and  
86 Medicines" or "Drug" or "Pharmac\*"). We combined these keywords with the filter "Randomized controlled  
87 trial", if the filter was not available on that data base then a keyword was used and the study's  
88 methodology was evaluated to ensure only randomized controlled trials were included. See Figure 1 for  
89 Prisma flow diagram.

### 90 **Inclusion/exclusion criteria**

91 The inclusion and exclusion criteria are detailed in Table 1. Studies were included in this review if they  
92 referred to a pharmaceutical care intervention in adult patients and the intervention included the role/input  
93 of a pharmacist. All healthcare settings were included i.e. both hospital and community based  
94 interventions. Studies were excluded if they were not written in English, did not have a full text article  
95 available, or if they were reviews, commentaries or letters to the editor. Studies published before 2004  
96 were also excluded. Our review's aim was to evaluate RCTs that assessed pharmaceutical care, so all  
97 studies were excluded if they were not RCTs, including cluster RCTs and any pilot data. RCTs were only  
98 included in this review if they measured patient outcomes that were either level 1 or 2 in the hierarchy of  
99 outcome measures (Table 2.)

100 **Jadad scores of methodology quality**

101 A quality assessment was completed for each randomized controlled trial using the Jadad checklist (24).

102 A Jadad score of equal to or greater than 3 is indicative of a high-quality study (19). The

103 assessment criteria for the Jadad scoring are detailed in Figure 2. The Jadad score has been

104 used as a tool in previous literature evaluating RCTs (19, 25).

105 **Table 1.** Study inclusion and exclusion criteria

No	Category	Inclusion criteria
1	Language of publication	English
2	Year of publication	2004-January 2017
3	Publication type	Full text RCTs discussing effect of pharmacy (pharmacists) services on patients health care outcomes.
4	Outcomes measures	RCTs measuring patient's outcomes i.e. clinical and surrogate outcomes (e.g. blood pressure (BP) control, blood glucose level, cholesterol BMI). Outcome measures must fall in level one or two of the hierarchy of outcome measures, described in table 2.
5	Methodology	Studies included, must demonstrate pharmacist's induced interventions by patient's homes visits or in any of healthcare setting including primary, secondary or tertiary health care settings or nursing home residents.
6	Pharmacists role	Pharmacist must play the significant or integral role, where multidisciplinary models were presented.
7	Patients	Adult patients only.
No		Exclusion criteria
1	Language of publication	Published in other than English
2	Year of publication	Published before 2004
3	Publication type	Abstracts, reports, commentaries, editorials, book chapters, reviews, secondary research (systematic reviews, meta-analysis)
4	Outcomes measures	RCTs with only patient's satisfaction as an outcome measure
5	Methodology	RCTs published as protocol of study
6	Methodology	Pilot studies were excluded
7	Methodology	Cluster RCTs

106



## 107 **Results**

### 108 **Studies selection**


109 The literature search identified 669 titles/abstracts that contained the aforementioned key terms. The titles  
110 and abstracts of all selected articles were reviewed for relevance. The search results were further  
111 checked and reviewed by a second author. In case of any doubt regarding papers, the full text article was  
112 reviewed for relevance. Inclusion criteria were formulated in relation to the research aims.

113 A total of 218 studies were screened and assessed for eligibility. Of these 54 RCTs fulfilled the inclusion  
114 criteria. The flow diagram (Figure 1) details the process in which the studies were identified, screened  
115 and included in this review. The inclusion and exclusion criteria of study are summarized in Table 1.

### 116 **Data extraction and analysis**

117 Two researchers (LC, RK) independently extracted study characteristics, using an extraction table. One  
118 researcher (LC) compared all extracted data and discussed discrepancies with other researchers (ZB)  
119 when necessary. The data were then grouped based on the condition that they aligned with and a  
120 summary of the data extracted from the studies is presented in Tables 3-8. This includes the country of  
121 origin, patient group included, follow-up period, number of patients in each arm, setting, description of the  
122 intervention outcomes measured, level of hierarchy of outcome measured and a summary of results.

Figure 1: The process of identification, screening and inclusion of papers for this review.



126 **Table 2.** Hierarchy of outcome measures (Adapted from AHRQ, 2001)(26)

Level	Description
1	Clinical outcomes - morbidity, mortality, hospitalizations
2	Surrogate outcomes - observed errors, intermediate outcomes (eg, laboratory results) with well-established connections to the clinical outcomes of interest (usually adverse events).
3	Other measurable variables with an indirect or unestablished connection to the target safety outcome (e.g., pre-test/post-test after an educational intervention, operator self-reports in different experimental situations)
4	No outcomes relevant to decreasing medical errors and/or adverse events (e.g., study with patient satisfaction as only measured outcome; article describes an approach to detecting errors but reports no measured outcomes)

127

128 **Figure 2.** Quality assessment of included randomized controlled trials through the Jadad checklist (24)

Assessment questions to ascertain Jadad score
<ol style="list-style-type: none"> <li>1. Study randomized?</li> <li>2. Randomization was described and appropriate?</li> <li>3. Study double blind?</li> <li>4. Double blinding was described and appropriate?</li> <li>5. Withdrawals and dropouts were described?</li> </ol> <p>Totals added to produce Jadad score (max 5)</p>

129

### 130 **Studies Characteristics**

131 The included studies (n=54) were performed over a number of countries including Australia (n=2),  
132 Belgium (n=2), Brazil (n=6), Canada (n=2), Chile (n=2), China (n=4), Colombia (n=1), Denmark (n=1),  
133 Hong Kong (n=2), Iraq (n=1), Jordan (n=5), Malaysia (n=2), Norway (n=1), Portugal (n=1), Spain (n=2),  
134 Sudan (n=1), Sweden (n=1), Taiwan (n=1) Tasmania (n=1), Thailand (n=1), the United Kingdom (UK)  
135 (n=4), United States of America (USA) (n=8) and United Arab Emirates (UAE) (n=3). All of the studies  
136 were conducted within the specified country, i.e. not over more than one country.

137 The targeted population included patients with specific condition(s) or those on a specific therapy. The  
138 RCTs can be further categorized into the following categories based on therapeutic condition;  
139 cardiovascular (CV) conditions (n=24), diabetes (n=15), depression (n=2), older adults (n=6), respiratory  
140 (n=3) conditions or other studies (those on multiple medicines, osteoporosis and epilepsy) (4).

141 The RCTs included in the review involved follow up period from 30 days to 36 months. The most common  
142 follow-up periods were as follows: 19 RCTs included interventions with a follow up period of 6 months,  
143 seventeen RCTs with 12 months, and six studies with 3 months follow-up. Follow-up was conducted in  
144 some studies by face-to-face meetings; others used web-based communications and telephone contact.

### 145 **Jadad scores of methodology quality**

146 Randomized controlled trials with a Jadad score equal to or greater than 3 are indicative of a high-quality  
147 study (19). In this review the Jadad scores were recorded in the data extraction tables. Forty-six of the  
148 studies in this review ranked 3 or above in the Jadad scale. One study ranked a 5 score. The main  
149 reason for loss of points on this score chart was nature of the study design i.e. not being double-blinded.

### 150 **Interventions**

151 The majority of the pharmaceutical care interventions assessed by RCTs in this review included  
152 educational interventions for patients. Educational interventions involved the verbal or written information  
153 to improve the knowledge and awareness of patients regarding their diseases. Behavioral interventions  
154 included changes in patient compliance by modifying their attitude to medication adherence to drug  
155 therapy.

156 Some RCTs used one of the above interventions as single and others applied in combination  
157 (multifaceted). The interventions were applied and their effects on patient's health care outcomes  
158 including clinical outcomes (morbidity, mortality, and hospitalizations) and surrogate clinical outcomes  
159 (laboratory results) were measured. Table 3-8 summarizes important characteristics of the studies  
160 included in the review.

161 Some studies used the Dader method of pharmaceutical care. This method includes "patient education  
162 about CV drugs, completion of a drug therapy profile and/ or drug history, assessment of drug  
163 compliance, patient counseling about lifestyle modifications, pharmacist-performed interventions not  
164 related to changes in drug therapy, and pharmacist-delivered treatment recommendations to physicians"  
165 (27).

166 In many RCTs in this review, follow-up took place on a frequent regular basis through the study, whereby  
167 a pharmacist contacted the patient either via home visits, appointments or via the telephone.

#### 168 **Outcomes**

169 This review sought to identify RCTs that had evaluated pharmaceutical care interventions in patients  
170 across all conditions. The outcomes that we were interested in were those that are described in table 2,  
171 meeting criteria one or two, i.e. hospitalizations or unintended use of medical care, mortality and clinical  
172 outcomes that have been shown to be directly related to the progression/severity of the condition. In  
173 some instances these studies also reported other measures, which have been included in the table for  
174 completeness but are not discussed in the results section. Criteria that each study reported are recorded  
175 in the level of outcome measure in the tables 3-8.

176 **Table 3.** RCTs evaluating pharmaceutical care in cardiovascular disorders (n=24)

Reference and country	Jadad score	Sample size (completed follow up)	Study population	Follow up period	Setting for study recruitment	Study outline (Intervention provided)	Outcome Measure	Level of outcome measure (L)	Effect of intervention
AMARILES et al. 2012 (27) Spain	3	714 patients (Control=358, Intervention = 356)	Aged between 25-74 years Prescribed with at least one drug indicated for CVD or CV risk factors	8 months	Multicenter community pharmacies	Comparison between control and intervention group on the bases of Dader method for pharmaceutical care provided to intervention group only. Patients had at least 5 appointments with the pharmacist throughout the time frame.	BP,TC & BP/TC	L2	Statistical significant difference in all measures.
BELL et al. 2016 (28) USA	3	851 patients (Controls = 428; Intervention = 423)	Adults hospitalized with a diagnosis of acute coronary syndrome and/or acute decompensated heart failure	30 days	Vanderbilt University Hospital (VUH) and Brigham and Women's Hospital (BWH)	Reconciliation of preadmission medications and discharge medications with the patient and reported to the medical team. Provided tailored counselling to patient. At discharge, the pharmacist provided additional counselling, a written information chart and showed patient how to use pillbox. After hospital discharge, study coordinators contacted the patients for follow-up.	Time to first unplanned health care utilization.	L1	Statistically significant difference in unplanned health care utilization among patients with inadequate health literacy
Community Pharmacy Medicines Management Project Evaluation Team. 2007 (29) UK	2	1493 patients (Control=513, Intervention = 980), 62 pharmacists & 164 general physicians.	Aged > 17 years, registered with general practices & with Coronary heart disease	12 months	9 study sites from primacy care organizations (community pharmacies with private consultation areas)	Consultation included: assessment of therapy and medicines. Compliance, lifestyle & social support	<b>Primary outcomes:</b> Proportion of pts receiving secondary prevention treatment for CHD, Health status (SF36, Euro QOL), health economic analysis. <b>Secondary outcomes:</b> 5-yr risk of CV death, patient satisfaction & compliance.	L2&3	No statistical significant difference.  Statistical significant difference in NHS-related cost.  No significant difference in 5-yr risk but significant difference in satisfaction
DE CASTRO et al. 2006 (30) Brazil	4	64 patients (Control=34, Intervention =30)	Aged ≥ 18 years , having uncontrolled hypertension, receiving treatment for hypertension	6 months	Hospital de Clinicas de Porto Alegre	Pharmaceutical care provided by 9 trained pharmacists. Patients were also provided printed educational material. Control group patients were allocated to sham intervention. 5 meetings were conducted over the time period with a pharmacist. The intervention was compared	BP measured by ABP monitoring  Medication adherence  DRP identification	L2&3	Decrease in BP in intervention group.  No significant difference in adherence  31 out of 37 DRP in intervention group were provided specific

						to sham condition.			intervention
FIRMINO et al. 2015 (31, 32) Brazil	3	36 patients (Controls = 15; Intervention = 21)	Patients with systemic hypertension who had uncontrolled blood pressure (BP) and/or presence of cardiovascular risk factors, or difficult control and adherence problems to the treatment	9 months	The pharmacy unit of Dr. Anastacio Magalhães Primary Health Care	Intervention group received orientation about taking medicines, actions aiming to prevent/solve medicine interactions and adverse effects and non-pharmacological interventions for 9 months	Glucose, total cholesterol and its fractions, triglyceride and BP measurements to calculate cardiovascular risk rate and Framingham score.	L2	Significant difference in cardiovascular risk rate and Framingham score.
GARCIA et al. 2015 (33) Norway	3	94 patients (Control = 46; intervention 48)	Only patients with established CHD were eligible for inclusion.	12 months	University Hospital of North Norway	Intervention group follow-up from the clinical pharmacist at three points of time; after discharge at the ward and at 3 months and 12 months at the hospital pharmacy .	Primary outcomes: adherence to clinical guideline recommendations concerning prescription, therapy goal achievement and lifestyle education. Secondary outcomes: changes in the biomedical risk factors cholesterol, BP and blood glucose.	L2&3	Overall adherence was significantly higher in the intervention group. No other significant differences.
GREEN et al. 2008 (34) USA	5	730 patients (Control = 247; Group 2 = 246; Group 3 = 237)	Patients with a hypertension diagnosis and taking antihypertensive medication.	12 months	10 medical centers	Two intervention groups. Group 2: Home BP monitoring and secure patient Web site training only, or group 3: home BP monitoring and secure patient Web site training plus pharmacist care management delivered through Web communications.	Percentage of patients with controlled and changes in systolic and diastolic BP	L2	Significant differences in the pharmacist group for all measures.
HAMMAD et al 2011 (35) Jordan	3	65 patients (Control = 22; Intervention 43)	Patients with metabolic syndrome as defined by the NCEP/ATP III criteria.	6 months	Outpatient clinics	Monthly meetings with the pharmacist. Pharmacists provided medication counselling, answered questions, offered instructions on self-monitoring BP and advised patients on healthy lifestyle choices. Educational materials were also distributed to patients in the intervention group, including brochures	Metabolic syndrome status, changes in mean values for each metabolic syndrome component (waist circumference, triglycerides, HDL-C, fasting blood glucose, and systolic and diastolic BP) and for body weight.	L2	Statistical significance in mean TG, SBP and DBP measures.
HOLLAND et al 2007 (36) UK	3	291 patients (Control = 143; Intervention	Patients with heart failure from three hospitals who had been	6 months	Outpatient (Discharged from hospital emergency).	Two home visits by a community pharmacist within two and eight weeks of discharge. Pharmacists reviewed drugs and	Primary outcome: total hospital readmissions at six months. Secondary outcomes:	L1&2	No significant difference in any measure

		= 148 )	admitted to the emergency room (on discharge).			gave education on the condition, symptom self-management and lifestyle advice and advised use of symptom diary.	mortality and QOL		
LALONDE et al. 2008 (37) Canada	3	150 patients (Control = 122; Intervention = 128 )	Patients prescribed warfarin that had no anticoagulation treatment in the past 24 months.	3 months	Community hospital	Follow up by pharmacist-managed anticoagulation services	INR control, incidence of complications, HRQOL, use of health care services, and direct incremental cost of PMAS	L1, 2 &3	No significant differences.
LEE et al 2006 (38) USA	3	159 patients (Control = 76; Intervention = 83 )	Aged >75 who were taking 4 or more medications	6 months	Walter Reed Army Medical Center's Armed Forces Retirement Home	Patients in the intervention group met with pharmacists every 2 months, and were provided blister- packed medications and also continued medication education as needed.	Primary outcome: proportion of pills taken vs baseline; secondary end points: changes in BP and LDL-C	L2&3	Significant differences in adherence and systolic BP
LEE et al 2009 (39) Hong Kong	3	118 patients (Control = 60; Intervention = 58)	Patients taking one or more lipid-modifying agents for dyslipidemia; who had a baseline lipid profile not reaching targeted LDL-C goal	Unclear; within 16 weeks	Outpatient clinics	Patients in the intervention group were counselled and provided with written information. A phone follow-up was done every 4 weeks between the initial counselling and the next follow-up interview for each patient.	LDL-C, HDL-C, TC and TG	L2	Significant differences in the pharmacist group for all measures.
MA et al 2010 (40) USA	3	554 patients (Control = 261; Intervention = 293 )	Known coronary heart disease	12 months	Cardiac catheterization laboratories at hospital.	Participants in the PI condition received 5 pharmacist-delivered telephone counselling calls post-hospital discharge. Also received an education packet, dietary goal booklet, medicine card and pillbox.	Percentage of patients with a serum LDL-C level <100 mg/dl	L2	No significant difference
MORGADO et al 2011 (41) Portugal	3	197 patients (Control = 99; Intervention = 98)	Hypertensive patients	9 months	Outpatient clinic in a teaching hospital	The pharmacist interventions, aimed to increase medication adherence and BP control, involved educational interventions and counselling tips directed to the patient and involved a quarterly follow up for 9 months	Systolic BP, diastolic BP and BP control, and adherence	L2	Significantly lower sBP, dBP, BP control and adherence
MURRAY et al 2007 (42) USA	3	270 patients (Control = 164; Intervention = 106)	Low-income patients with heart failure	9 months	University-affiliated, inner-city, ambulatory care practice.	When medications were dispensed, the pharmacist provided patient-centered verbal instructions and written materials about the medications written for those with low health literacy. Monthly calls to assess QOL and interviews at 3, 6, 9, and 12	Primary outcomes: adherence and exacerbations requiring emergency department care or hospital admission. Secondary outcomes: included health-related quality of life, patient	L1,2&3	Reductions seen but 3 months post intervention dissipated



						months.	satisfaction with pharmacy services, and total direct costs.		
PAULOS et al 2005 (43) Chile	1	42 patients (Control = 19; Intervention = 23)	Those who purchased their medication or requested blood cholesterol or triglyceride analysis	16 weeks	Outpatient pharmacy	Intervention included obtaining total blood cholesterol and triglyceride levels as well as patient education. Patients had five follow-up appointments	Total blood cholesterol level, triglyceride level, and body mass index (BMI) and adherence & QOL.	L2&3	Total cholesterol and TG significant improvements.
PETERSON et al 2004 (44) Tasmania	3	81 patients (Control = 42; Intervention = 39)	Patients with dyslipidaemia.	6 months	Royal Hobart Hospital	Intervention group were visited at home monthly by a pharmacist, who provided education, assessed patients for drug-related problems, and measured total blood cholesterol levels using point-of-care testing.	Blood cholesterol levels	L2	Significant improvements in the cholesterol levels in the intervention group
PLASTER et al. 2012 (45) Brazil	2	74 patients (Control=36, Intervention = 38)	At least 3 of conditions recommended by the NCEP-ATP III & BGMS for the diagnosis of metabolic syndrome.	6 months	Out patients of a primary health care unit (CHC)	Patients participated in PC program according to the Dader methodology	Mean Arterial Pressure (MAP), NOM, adherence level (Morisky test), CVD risk.	L2&3	Statistical significant improvements in CVD risk
QUDAH et al 2016 (46) Jordan	3	52 patients (Control = 25; Intervention = 27)	Hypertensive patients receiving hemodialysis	3 months	Outpatient hemodialysis units of Jordan University Hospital and Isra'a Hospital	Doctor-pharmacist collaboration in addition upon enrolment, educational materials were distributed and discussed with patients in the intervention arm. Monthly follow-up by pharmacist for DRP and education.	% of patients achieving BP below or equal 135/85 mmHg. Secondary measures that were assessed include absolute reduction in peridialysis BP, interdialytic weight gain, adherence to medications and dialysis sessions	L2&3	Statistical significance in the % of patients reaching BP target and weekly home systolic BP measurements
SADIK et al. 2005 (47) UAE	3	208 patients (Control=104, Intervention = 104)	Diagnosed with heart failure & cognitive status	12 months	Al-Ain Hospital	Patients were education on HF, prescribed medications & management of HF symptoms, self- monitoring program. Printed booklet was also provided.	2-min walk test, forced vital capacity, SBP, DBP & pulse, QOL questionnaire (MLHFQ, SF36). Patient assessment questionnaires for medication knowledge & self- reported compliance	L1,2&3	Statistical significant difference
SOOKANEKUN N et al 2004 (48) Thailand	3	235 patients (Control = 117; Intervention = 118)	Hypertensive patients	6 months	Maharakham University pharmacy and 2 primary care units	The patients in the intervention group had monthly consultations The research pharmacist assessed the patient's understanding of medications, counselled on the use of their	BPs, tablet counts, lifestyle modifications	L2&3	Significant reductions in the systolic and diastolic BP and Patients whose BP stabilized and in adherence

						medications, assessed adherence and lifestyle habits, reviewed for adverse events due to drug-related problems, and discussed factors associated with uncontrolled BP and disease state control and made recommendations to the prescriber. Educational leaflets were also given			
VILLA et al 2009 (49) Chile	2	142 patients (Control = 57; Intervention = 85 )	Diagnosed with dyslipidaemia	32 weeks	Primary Health Care centers	Intervention group patients received care twice a month by pharmacists and drug related problems were identified.	Knowledge about their illness and medications, adherence to drug therapy, and quality of life. In addition to HDL-c, LDL-c, TG and TC	L2&3	Significant improvements in all measures apart from HDL-c
WANG et al 2011 (50) China	3	59 patients (Control = 30; Intervention = 29)	Hypertensive patients	12 months	Outpatient receiving antihypertensive drugs	Intervention group received education and met with clinical pharmacists every 2 months. Any drug related problems identified were reported to the physician.	SBP and DBP plus adherence	L2&3	Significant differences in SBP and DBP
ZHAO et al. 2012 (51) China	3	Control=129 , Intervention =129	Aged b/w 21-85 years, diagnosed with hypertension,	6 months	Xijing Hospital	Recommendations to physicians and educational and counselling directly to patients. Follow-up at 6 months at clinic.	SBP, DBP, BP control and medication adherence	L2 &3	Significant difference

177

178

179 **Table 4.** RCTs evaluating pharmaceutical care in diabetes mellitus (n=15)

Reference and country	Jadad score	Sample size	Study population	Follow up period	Setting for study recruitment	Study outline (Intervention provided)	Outcomes Measure	Level of outcome measure (L)	Effect of intervention
AL MAZROUI et al. 2009 (52) UAE	3	234 patients (control=117 ; intervention = 117)	Diagnosed with type 2 diabetes mellitus, oral hypoglycemic therapy.	12 months	Zayed Military hospital	The intervention group received patient education about illness & medication, provided with leaflets, behavioural modifications from a pharmacist. The intervention group had 4 monthly appointments at hospital	BMI, fasting blood glucose level, HbA1c, BP, serum TC, LDL-C, HDL-C TG, HRQOL, 10-years risk assessment, disease knowledge & med. adherence	L2&3	Statistical significant difference in all measures.
CHEN et al. 2016 (53) Taiwan	3	100 (control = 50; intervention 50)	Diagnosed with type two diabetes with poor control	6 months	Nantou City hospital	Intervention group received pharmaceutical care including identification and resolution of drug-related problems and established a consultation procedure.	HbA1c Hospitalizations were also monitored	L1&2	Statistical significant difference in HbA1c.  One person was hospitalized in the control group, none in the intervention group
CHUNG et al 2014 (54) Malaysia	1	241 (Control= 121, Intervention = 120)	Diagnosed with type 2 DM, taking at least one antidiabetic medication	12 months	Malaysian Teaching Hospital	Patient education on diabetes, hypertension, hyperlipidemia and medication adherence. Taught how to use a pill box, blood glucose meter and how to record readings. Received monthly calls from pharmacist. Data collected at baseline and at 4, 8 and 12 months.	Fasting blood glucose (FBG), HbA1c. Medication adherence.	L2&3	Statistical significant difference in HbA1c at month 4, 8 and 12 and on medication adherence.
CLIFFORD et al. 2005 (55) Australia	3	180 (control = 88; intervention 92)	Diagnosed with type two diabetes. Enrolled in the Fremantle Diabetes study	12 months	Community based patients	Counselling at 6 and 12 months in addition to 6 weekly telephone calls Diet, exercise and compliance was encouraged. Educational pamphlets were provided	BMI, systolic and diastolic BP, fasting plasma glucose, HbA1c, serum lipid parameters and urinary albumin-to-creatinine ratio and exercise	L2&3	Statistical significant difference in BMI, systolic and diastolic BP, fasting plasma glucose, and HbA1c
DOUCHETTE et al. 2009 (56) USA	2	66 (control = 35; intervention = 31)	Diagnosed with type two diabetes who had completed two education sessions previously.	12 months	Community based patients	Four visits by a trained pharmacist at community pharmacy to assess any issues patient had. Diabetes clinic at the start and end of study.	HbA1c, BP, LDL-cholesterol, diet self-care activities, diabetes self-care activities, exercise self-care activities	L2&3	Only self-care activities had a significant effect.
ELNOUR et al. 2008 (57) UAE	3	165 patients (control= 66, intervention = 99)	Diagnosed with gestational diabetes, within first 20 weeks of gestation, UAE national.	6 months	Al-Ain Hospital, UAE	Patients were educated on GDM & its management, insulin administration & storage, plasma glucose measurement. Provided with booklet.	HRQOL (SF36), diabetes knowledge, insulin & plasma glucose monitoring, HbA1c, BP. Maternal & neonatal complications.	L1&2	Significant differences in HRQOL scores, plasma glucose, insulin use, glucose monitoring & some maternal & neonatal

									complications.
JAMESON et al. 2010 (58) USA	3	103 (controls= 51; intervention = 52)	Diagnosed with type two diabetes.	12 months	Community based patients	Patient intervention included regular care plus medication management, patient education, and disease control. 6 office visits and 3 phone calls to patients	HbA1c	L2	Statistically significant difference overall
JARAB et al. 2012 (59) Jordan	3	156 (control = 77; intervention 79)	Diagnosed with type two diabetes.	6 months	Outpatient diabetes clinic	Patients received face-to-face education and necessary lifestyle changes, followed by 8 weekly telephone follow-up calls.	HbA1c, BP, lipid values, self-reported medication adherence, and self-care activities	L2&3	Statistically significant difference in all measures apart from BMI and HDL-cholesterol and adherence.
MAHWI et al. 2013 (60) Iraq	3	123 patients (control= 61, intervention =62)	Diagnosed with type 2 diabetes mellitus	3 months	Diabetic centre in Sulaimani	Intervention group received pharmaceutical care	HbA1c, fasting plasma glucose. Drug therapy problems & med. compliance	L2&3	Statistical significant difference in fasting plasma glucose and HbA1c.
MCLEAN et al 2008 (61) Canada	3	211 patients (Control = 109; Intervention = 102)	Patients with diabetes with BP >130/80mmHg on 2 screening visits separated by 2 weeks	24 weeks	Community pharmacy patients	The intervention was delivered by pharmacist-nurse teams at various pharmacy sites. Cardiovascular risk reduction counselling was provided. The patient received a wallet card documenting their BP. Intervention group patients were seen at 6-week intervals by the study nurse and pharmacist for counselling and measurement of BP.	Primary outcome: Change in SBP. Secondary outcomes: BP targets <130/80mmHg, change in antihypertensive drug therapy, the proportion prescribed an angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist, and change in SBP in patients >160 mm Hg.	L2	Statistical significant difference in systolic BP and also proportion of patients who achieved the goal BP of less than or equal to 130/80 mm Hg
MOURAO et al. 2013 (62) Brazil	3	100 (control = 50; intervention 50)	Diagnosed with type two diabetes, using oral antidiabetic medications and presenting Hb A1c>7	6 months	Six primary health care units	Designed a care plan for each patient focusing on patient education/pharmacotherapy changes	HbA1c level, fasting blood glucose, TC*, LDLc, HDLc, DBP, SBP	L2	Statistical significant improvement in all biochemical data & SBP (except BMI & DBP)
OBRELI-NETO et al. 2011 (63) Brazil	3	194 Control=97 Intervention =97	Aged ≥60 years, Diagnosed with diabetes or hypertension.	36 months	Primary public health care unit (PHCU)	The interventions include assessment of non-adherence, discussions of the role of medication in their health, correct use of drugs and a visual aid. Group activities were carried out every 6 months. These discussed adherence, dangers of self-medication and correct storage of medicines.	SBP, DBP, LDL--cholesterol, HbA1c, fasting blood glucose, QALY	L2&3	Statistical Significant difference in surrogate outcomes. Cost effective ICER*/QALY
ODEGARD et al 2005 (64) USA	3	77 (control – 34; intervention	Diagnosed with type two diabetes with HbA1c >9 and	12 months	University of Washington Neighbourhood	Diabetes care plan followed by weekly visits or telephone calls, which was reduced to less	HbA1c, adherence	L2&3	No significant differences

		= 43)	taking >1 oral antidiabetic		d Clinics	frequent when needs were progressing.			
WISHAH et al. 2014 (65) Jordan	3	101 (control = 51; intervention 50)	Diagnosed with type two diabetes	6 months	Jordan University hospital outpatient clinic	Patient education about the condition and complications, lifestyle advice, medicines, adherence and written material. Follow-up phone calls to remind patients of adherence and of the appointments for follow-up visit.	HbA1c, fasting blood glucose, patient knowledge	L2&3	All measures show significant differences
XIN et al. 2015 (66) China	3	240 (control = 120; intervention 120)	Diagnosed with type two diabetes, newly prescribed insulin therapy	12 months	Tongde Hospital	Patients received individualized education, educative group activities, and telephone counselling. Group activities were carried out every 6 months. These discussed adherence, dangers of self-medication and correct storage of medicines.	HbA1c, hospitalization, measures of adherence	L1, 2 &3	Significant differences in HbA1c and hospitalizations

180

181 **Table 5.** RCTs evaluating pharmaceutical care in depression (n=2)

Reference and country	Jadad score	Sample size	Study population	Follow up period	Setting for study recruitment	Study outline (Intervention provided)	Outcome Measure	Level of outcome measure (L)	Effect of intervention
MARQUES et al 2013 (67) Brazil	3	48 patients (Control= 22, Intervention= 26)	Patients with depression	3 months	Outpatient clinic	Pharmaceutical intervention according to the Dáder Method, receiving visits every 30 days, or more frequently if necessary. Oral and written information were given.	Beck Depression Inventory and Beck Anxiety Inventory	L2	Statistically significant difference in the Beck Depression Inventory score and Beck Anxiety Inventory score
RUBIO-VALERA et al 2013 (68) Spain	3	151 patients (Control= 87, Intervention= 64)	Patients with depression	6 months	4 Primary Care Health Centres	Adherence, satisfaction with service, HRQOL and clinical severity. Follow-up visits to monitor progress,	Outcome measurements included clinical severity of depression (PHQ-9), health-related quality of life (HRQOL) (Euroqol-5D) and satisfaction	L2&3	Statistically significant difference in HRQOL

182

183 **Table 6.** RCTs evaluating pharmaceutical care in older adults (n=6)

Reference and country	Jadad score	Sample size	Study population	Follow up period	Setting for study recruitment	Study outline (Intervention provided)	Outcome Measure	Level of outcome measure (L)	Effect of intervention
CROTTY et al. 2004 (69) Australia	3	110 patients (Control= 54, Intervention= 56)	Hospital patients awaiting discharge to a long term care facility	8 weeks	Hospital patients awaiting discharge to a long term care facility	A medication review Within 10 to 14 days of the transfer. The transition pharmacist, patient, family physician, the community pharmacist, and a registered met between 14&28 days post transfer. Education concerning medication use and appropriateness was given.	Hospital usage, Medication Appropriateness Index, adverse drug events, falls, worsening mobility, worsening behaviors, increased confusion, and worsening pain.	L2 &3	Significant differences in hospital usage and worsening pain
HOLLAND et al. 2005 (70) UK	3	829 patients (Control= 414, Intervention= 415)	Home based medication review after discharge from acute or community hospitals	6 months	Home based medication review after discharge from acute or community hospitals in UK	Two home visits post discharge to educate patients and carers about their drugs, inform general practitioners of drug reactions or interactions.	Total emergency readmissions. Secondary outcomes included death and quality of life	L1, 2&3	Significant differences in hospital readmissions and QOL scores
LENAGHAN et al. 2007 (71) UK	3	105 patients (Control= 49, Intervention= 56)	> 80 years of age, living at home, taking four or more medicines, and had at least one additional medicines-related risk factor.	6 months	Home-based medication review	Two home visits for education of patient/carer about their medicines, pharmaceutical care issues were noted, assessed need for an adherence aid	Hospital admissions, QOL scores & number of medication prescribed	L1&3	Significant reduction in the mean number of medicines prescribed
LENANDER et al 2014 (72) Sweden	2	141 patients (Control= 66, Intervention= 75)	> 65 years with five or more different medications	12 months	GP practice	A medication review was performed open for patients questions Drugs and dosages were evaluated and patients were asked about concordance. Concluding pharmaceutical advice was given to patients and entered into the computerized patient record. Follow up at 12 months	Hospitalizations, self-rated health, drug related problems and number of drugs	L1&3	Significant differences in drug related problems, in the number of medications
OLESEN et al. 2014 (73) Denmark	3	517 patients (Control= 264, Intervention= 253)	Aged $\geq$ 65 years, with a least 5 current prescription drugs taken without assistance.	24 months	Patients were visited by pharmacists at their homes.	Medication review. Informed the patients about drugs, provided information leaflets & motivated adherence. Follow-up telephone call at 3, 6 and 9 months,	<b>Primary outcomes</b> Treatment adherence assessed by a pill-count. <b>Secondary outcomes</b> DRPs, hospitalization & mortality	L1&3	No significant difference.

SPINEWINE et al. 2007 (74) Belgium	3	172 patients (Control= 83, Intervention= 89)	Aged >70 with geriatric problems	12 months	Acute Geriatric Evaluation and Management unit	Pharmaceutical care was performed The appropriateness of treatment was analyzed, and a pharmaceutical care plan was prepared. At discharge, the pharmacist provided written and oral information on treatment changes to the patient or caregiver, as well as written information to the general practitioner.	Medication Appropriateness Index (MAI), Beers criteria, and Assessing Care of Vulnerable Elders (ACOVE) underuse criteria and mortality, readmission, and emergency visits.	L1&2	Significant differences in the MAI and in the ACOVE underuse criteria
------------------------------------	---	--	----------------------------------	-----------	--	--	---	------	---

184

185



186 **Table 7.** RCTs evaluating pharmaceutical care in respiratory conditions (n=3)

Reference and country	Jadad score	Sample size	Study population	Follow up period (months)	Setting for study recruitment	Study outline (Intervention provided)	Outcome Measure	Level of outcome measure (L)	Effect of intervention
ABDELHAMID et al. 2008 (75) Sudan	3	78 Patients (Control=30, Intervention=48)	Diagnosed with asthma	6 months	Shaab Teaching Hospital	Drug therapy for asthma was reviewed; patients were educated about the disease, non-drug therapy measures, pharmacotherapy, self-management & inhalation technique every two weeks.	Frequency of acute attacks, nocturnal symptoms, using short acting inhaled $\beta$ 2-agonist, days of sickness per week.	L1, 2 & 3	Statistical significant difference in frequency of attacks, nocturnal symptoms and frequency of reliever use. Also significant difference in the days sick. Patient inhaler technique and knowledge also improved.
TOMMELEIN et al. 2014 (76) Belgium	3	692 patients (Control=346, Intervention=346)	Aged $\geq$ 50 years COPD patients, Prescribed with COPD medications	3 months	170 community pharmacies	Two session intervention one at the start and one at one month. Inhalation technique, med. adherence, hospitalization rate. Patients also given written information and demonstration units.	<b>Primary outcomes</b> Inhalation technique, med. adherence. <b>Secondary outcomes</b> Dyspnea, hospitalization rate, health status & smoking behavior.	L1&3	Statistical significant difference found in inhalation technique, adherence and hospitalization rates.
WEI et al. 2014 (77) China	3	87 patients (Control= 45, Intervention=42)	Stable COPD patients with a t least 2 consecutive visits to this hospital for COPD treatment	12 months	Medical University affiliated Hospital	A comprehensive pharmaceutical care program composed of individualized patient education & a series of telephone counselling 5-6 sessions.	<b>Primary outcomes</b> Medication adherence by pill-count & questionnaire. <b>Secondary outcomes</b> Severe exacerbation rate & HRQOL.	L1&3	Statistical significance in adherence, hospital admissions and symptoms and impact.

187

188 **Table 8.** RCTs other studies evaluating pharmaceutical care (n=4)

Reference and country	Jadad score	Sample size (completed follow up)	Study population	Follow up period (months)	Setting for study recruitment	Study outline (Intervention provided)	Outcome Measure	Level of outcome measure (L)	Effect of intervention
BASHETI et al. 2016 (78) Jordan	3	160 patients (Control=78, Intervention=82)	>18 years, at least one long term condition and prescribed >3 medications	Average 3 months	Community pharmacy	Baseline MMR was conducted for all patients, recommendations regarding the identified TRPs were only submitted to the physicians of patients in the intervention group. Follow-up then occurred at the end of the study.	Resolution of treatment related problems. Prescriber acceptance of the advice; effect of the intervention on certain clinical outcomes: blood glucose levels, BP, and triglyceride levels.	L2 &3	Significant difference in the treatment related problems that were resolved, blood glucose, BP and TG levels
LAI et al. 2011 (79) Malaysia	3	177 patients (Control=89, Intervention=88)	Aged ≥ 45 years Postmenopausal women diagnosed with osteoporosis, prescribed with once weekly alendronate or risedronate.	12 months	University Malaya Medical Centre (UMMC)	Counselling on osteoporosis, risk factors, lifestyle modifications, and goals of therapy, side effects & the importance of adherence. Written information given. Monthly follow-up calls for the first 6 months, then 3 monthly thereafter.	Medication adherence, BTMs and persistence	L3	Significant higher adherence.  No significant difference in persistence
LOSADA-CAMACHO et al. 2014 (80) Colombia	3	144 patients (Control=74, Intervention=70)	Aged >18 years, diagnosed with epilepsy from over a year, receiving out-patient treatment with anti-consultants, experienced at least one seizure in last 3 years.	6 months	Fundacion Liga Central Contra La Epilepsia, sede Bogota.	Applied a pharmaceutical care program consisting of 5 parts. Medication review follow up according to Dader's method, Lecture in group education sessions, Treatment adherence, registration of seizures & possible triggers, TDM of anticonvulsants	<b>Primary outcomes:</b> HRQOL measured by QOLIE-31(Quality of Life in epilepsy Inventory-31). <b>Secondary outcomes:</b> Frequency of crises, adverse reactions, depression & adherence	L1&3	Statistical significant difference in HRQOL.
WU et al 2006 (81) Hong Kong	3	442 patients (Control=223, Intervention=219)	> 5 medications and two appointments to the clinic	24 months	Specialist medical centre at hospital	Intervention group received a 10-15 minute telephone call from our pharmacist at the midpoint. The pharmacist asked about the patient's treatment regimens; provided education and reminded patients of their next clinic appointment; and reinforced the importance of compliance	The primary endpoint was death from any cause. Other endpoints included changes in the rate of admission to hospital.	L1	Statistically significant change in deaths

189 **Impact of pharmaceutical care in disease management**

190 **Cardiovascular disorders** (Table 3)

191 Twenty-four RCTs evaluated the impact of pharmaceutical care on the patients with cardiovascular  
192 diseases, of which 20 showed statistically significant clinical outcomes (27, 28, 30, 31, 34, 35, 38-51).  
193 Four studies showed no differences in the clinical outcome measures (29, 33, 36, 37) .

194 Table 3 illustrates the 24 RCTs that have been conducted on cardiovascular conditions. Included in this  
195 category are studies evaluating the effect of interventions on patients with cardiovascular diseases (e.g.  
196 heart failure (36, 42, 47) or coronary heart disease (28, 29, 33, 37, 40), in patients with high  
197 cardiovascular risk factors (27), hypertension (30, 31, 34, 38, 41, 46, 48, 50, 51) or dyslipidemia (39, 43,  
198 44, 49) and in two studies patients with metabolic syndrome (35, 45). The four studies that did not show  
199 significant differences in hospitalizations or clinical outcomes were in cardiac heart failure patients (36)  
200 and three in those with coronary heart disease (29, 33, 37).

201 To note, two studies included patients that had been diagnosed with diabetes and cardiovascular  
202 conditions; these studies were included and discussed in the diabetes section.

203 Clinical outcomes measured included BP, cholesterol levels blood glucose and cardiovascular risk.  
204 Eleven studies found significant differences in diastolic and/or systolic BP readings after the intervention  
205 (27, 30, 34, 35, 38, 39, 41, 46, 48, 50, 51). One study specifically aimed to evaluate whether patients met  
206 a target BP (46). Two studies found no significant differences in BP; one study by Garcia and colleagues  
207 (33) and another by Sadiq et al (47).

208 Cholesterol readings were compared in twelve RCTs (27, 29, 31, 33, 35, 38-40, 43-45, 49); these  
209 measures included total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-c),  
210 and/or high density lipoprotein cholesterol (HDL-c) levels. Statistically significant differences were seen in  
211 TC (27, 39, 43, 44, 49), TG (35, 39, 43, 49), LDL-c (39, 40, 49) and HDL-c (39).

212 Blood glucose was measured in two of the studies, but neither reported significant differences (33, 35).

213 Cardiovascular risk was calculated and compared in two studies. One study showed a significant  
214 reduction in CV risk after the intervention (31), but the other study showed no differences (29).

215 Hospitalization rates were recorded Murray and colleagues, who found statistically significant differences  
216 after a pharmacist intervention in patients with low incomes and heart failure, however this difference  
217 dissipated after the intervention stopped (42) Furthermore, Holland et al. reported no significant  
218 differences in patients with cardiac heart failure after pharmacist intervention post-discharge from  
219 hospital. Unplanned health care utilization was found to be statistically significant in patients  
220 with low health literacy in the study by Bell et al. (28).

221 Another study in patients with cardiac heart failure used exercise tolerance (2-minute walk), and  
222 forced vital capacity in order to evaluate the intervention, in addition to the measures described  
223 above. Statistical significant differences were found in both measures (47).

224 Lalonde and colleagues' RCT included patients who had been prescribed warfarin. They  
225 evaluated whether there were changes in INR control, complications and use of health care services,  
226 and found no differences after intervention by a pharmacist anticoagulation service (37).

#### 227 **Diabetes mellitus** (Table 4)

228 Fifteen of the RCTs assessed the effect of pharmaceutical care intervention on various outcomes of the  
229 patients diagnosed with diabetes mellitus (Table 4). The majority of these involved the patients with Type  
230 2 diabetes mellitus (52-56, 58-60, 62, 64-66), one study included both Type 1 and Type 2 patients (61)  
231 and one study was unclear regarding the type of patient that was included. One RCT involved the  
232 gestational diabetes mellitus patients (57).

233 Ten studies found the significant reductions in HbA1c levels in the intervention group (52-55, 57, 59, 60,  
234 62, 63, 65), a further three studies measured HbA1c and found no significant differences (56, 57, 64).

235 Nine RCTs measured the fasting plasma glucose level and significant reduction was observed in the  
236 pharmaceutical care group (52, 53, 55, 57, 59, 60, 62, 63, 65), compared with only one that did not find  
237 differences in fasting plasma blood glucose (54). Statistical significant decrease was found in total

238 cholesterol, LDL-cholesterol and/or systolic BP (52, 55, 59, 61-63, 82-84) and an increase in HDL-  
239 cholesterol (52, 62). One RCT also recorded improvements in some maternal and neonatal complications  
240 (57).

241 Hospitalizations and unexpected medical usage was recorded by a number of studies, but only reached  
242 statistical significance after a pharmaceutical care intervention in one study (66).

#### 243 **Respiratory conditions** (Table 5)

244 Three studies evaluated the impact of pharmaceutical care and medicines management on the  
245 respiratory disorders patients including asthma and chronic obstructive pulmonary diseases (COPD)  
246 (Table 5). Two of these solely involved the COPD (76, 77) and one patients with asthma (75).

247 Statistical significant differences were found in symptoms of the conditions i.e. frequency of attacks,  
248 nocturnal symptoms and frequency of reliever use in asthmatics (75) and exacerbations in COPD (77). In  
249 addition hospitalization rates were also statistically significant after intervention with pharmaceutical care  
250 (76, 77).

#### 251 **Depression** (Table 6)

252 Two RCTs included in this review focused on pharmaceutical care interventions in depression. Clinical  
253 outcomes measuring clinical severity in the intervention groups led to mixed results. One study found a  
254 significant difference (67) in clinical measures whereas the other did not (68). The latter study did lead to  
255 significant changes in HRQOL but not clinical severity.

256 **Older adults** (Table 7)

257 Six studies evaluated pharmaceutical care interventions in older adults, with mixed results (Table 6); four  
258 studies showed statistical significance in clinical outcomes or hospitalizations (69-71, 74), whereas two  
259 showed no difference (72, 73). Hospitalization rates were reported in all of the six RCTs, with two studies  
260 finding differences after intervention of pharmaceutical care (69, 70). One study reported significant  
261 differences in worsening of pain (69) and three studies reported improvements in appropriateness (74) or  
262 number (71, 72) of medicine prescribed.

263 **Other studies included** (Table 8)

264 *Multiple medications*

265 Two RCTs involved the implementation of interventions for patients who were on multiple medications;  
266 one study patients included in the RCT needed to be taking a minimum of three medicines (78) and the  
267 second study the patients needed to be taking five or more medications (81). The study by Basheti and  
268 colleagues (2016) was community pharmacy based using a medication management review and the  
269 primary outcome was resolution of drug related problems, acceptance of advice by prescribers plus  
270 clinical outcomes of blood glucose levels, BP and triglyceride levels. Significant differences were seen in  
271 drug related problems resolved and all clinical outcomes (78). The second study in this category was set  
272 in a specialist medical center and the primary endpoint was death of any cause and rate of  
273 hospitalizations. Differences were found in number of deaths (81).

274 *Epilepsy*

275 Losada- Camacho and colleagues (2014) evaluated the impact of pharmaceutical care program on  
276 women with epilepsy (80) (Table 8). The primary outcome was health related quality of life (HRQOL)  
277 measured by Quality of Life in Epilepsy Inventory-31 (QOLIE-31) and the secondary outcomes included  
278 the changes in frequency of seizures, depression measured by using the questionnaire of the Center for  
279 Epidemiologic Studies Depression Scale (CES-D), adverse drug reactions by Liverpool Adverse Event  
280 Profile (Liverpool AEP) and adherence by using Haynes-Sackett test and Moriski-Green test. Significant

281 differences were seen in QOLIE-31 scores. No significant differences were seen in the frequency of  
282 seizures.

283 *Osteoporosis*

284 A RCT assessed the effects of pharmaceutical care on adherence and persistence of bisphosphonate in  
285 postmenopausal osteoporotic women (79). Primary outcome measures were medication adherence, bone  
286 turnover markers (BTMs) and persistence (Table 8). Two BTMs serum C-terminal cross-linking  
287 telopeptide of type I collagen (CTX-I) and serum osteocalcin (OC) were assessed. No significant  
288 reduction was found in in CTX-1 and OC between the two groups (79).

**289 Discussion**

290 This systematic review aimed to evaluate the effectiveness of pharmaceutical care, based on RCTs that  
291 have been published between 2004 and January 2017. There have been a steady number of studies  
292 emerging over the past decade evaluating pharmaceutical care, leading to a high number of studies that  
293 were included in this review. Our findings suggest that pharmaceutical care, in the majority of cases, is  
294 effective in either decreasing hospitalizations or improving surrogate clinical outcomes particular to the  
295 presenting condition. The included studies are all RCTs, which are considered the gold standard of  
296 clinical effectiveness if the methodology is properly executed (19), however RCTs in pharmaceutical care  
297 are often challenging to conduct and this could be a reason for a bias toward studying certain conditions  
298 and not others – for example there are 24 studies for cardiovascular conditions versus 3 for respiratory  
299 conditions. The spectrum of papers include a wide a variety of interventions, outcome measures and  
300 follow-up frequency and schedules, often making it challenging for researchers and healthcare  
301 professionals to directly compare and evaluate why certain studies have not found significant results.

302 In addition to the current literature, our review has identified that there is strong evidence to support  
303 pharmaceutical care in long term conditions affecting patients with hypertension and dyslipidemia.  
304 Surrogate clinical outcomes of BP and cholesterol levels have shown to be systematically improved in the  
305 majority of studies; interestingly despite these two biomarkers being integral to the calculation of 5-year  
306 cardiovascular risk, only one study (out of two) showed significant improvements in 5-year cardiovascular  
307 risk. A systematic review published by Aguiar and colleagues (2012) focused on pharmaceutical care in  
308 hypertensive patients and found similar results to the present study (19). Systolic BP was the most  
309 positively impacted clinical outcome by the pharmaceutical intervention. The authors of the 2012 review  
310 described the need to improve research design, as there were limitations in hardness (19). In 2011  
311 Morgado and colleagues conducted a systematic review and meta-analysis of pharmacist interventions to  
312 enhance BP therapy; results of this review showed that pharmacist interventions can significantly improve  
313 medication adherence, systolic BP, diastolic BP, and BP control in patients with essential hypertension  
314 (20). However in this review, one important limitation noted by the authors were the databases available  
315 for the systematic review, potentially therefore missing potential eligible studies.



316 In this review, the outcomes in relation to CHF and CHD were mixed. It is not as clear whether  
317 pharmacist intervention via pharmaceutical care is as effective; this may be due to fewer RCTs available  
318 in these conditions. In 2008 Koshman et al. published a systematic review in patients with CHF, including  
319 studies prior to 2007. Despite inclusion of 12 RCTs, outcomes were similar to our current review; mixed  
320 results for HF hospitalizations (3 of 11 studies finding significant differences) and mortality rates showing  
321 no significant differences. Overall, when the authors of this study pooled responses for outcomes,  
322 benefits were seen in pharmacist intervention (85). Further studies need to be conducted to clarify the  
323 effectiveness of pharmacists in these conditions.

324 Pharmacists play a significant role in the provision of pharmaceutical care services in diabetes mellitus.  
325 Our findings show strong evidence that pharmaceutical care interventions have significant positive effects  
326 in the reduction of HbA1c level in patients with diabetes. This finding is similar to other studies that have  
327 focused on diabetes, for example Fornos et al. (86) and Balaiah et al. (87), where glycemic control was  
328 found to be significantly improved as a result of pharmaceutical care interventions; ultimately lowering of  
329 HbA1c being a predictor of improved therapeutic outcomes of patients (88).

330 A previous Cochrane review did not show that pharmaceutical care is effective in older adults (89), this  
331 current review reported mixed outcomes for hospitalizations and included measures of appropriateness of  
332 medications and health related quality of life. Our study focused on surrogate clinical outcomes and  
333 hospitalizations and included six RCTs, with an overall unclear conclusion regarding the benefit of  
334 pharmaceutical care intervention in this population. Four studies showed improvements after  
335 pharmaceutical care interventions, whilst two did not. This is also in line with a previous review by Holland  
336 and colleagues who concluded that pharmaceutical care does not impact on hospitalizations and  
337 mortality, however the authors do suggest that interventions could potentially improve knowledge  
338 and adherence (90).

339 The three respiratory studies were included in this review, all showed significant changes after a  
340 pharmaceutical care intervention. Health resource utilization (76, 77), symptoms (77) and inhalation  
341 techniques (76) were found to be improved in COPD patients. Similar results were seen in asthmatic  
342 patients, with improvements in symptoms, frequency of attached and reliever use (75).

343 No significant differences in hospitalizations or clinical surrogate outcomes were seen in patients with  
344 epilepsy, osteoporosis and depression. This could be due to the limited studies that have been  
345 conducted, and in the case of the study by Losada-Camacho et al. a relatively low number of patients  
346 returned their seizure diary (80).

347  
348 Like previous literature, this study highlights the potential that pharmaceutical care has in a number of  
349 conditions, but goes further to identify some conditions that pharmaceutical care may not lead to changes  
350 in clinical outcomes. These non-significant results are challenging to interpret, they could be due to a  
351 myriad of factors including shorter follow up period insufficient for the examination of intervention effects  
352 and measurement of endpoints, the training of the pharmacists involved, the frequency of monitoring in  
353 the staff and the nature of those follow-up sessions.

354 This review also highlights the need for consistency across studies in the future in terms of the clinical  
355 outcomes measured. Despite grouping the studies in this review into condition groups, within each  
356 condition there was a wide range of outcomes reported. This makes it challenging to be able to conduct a  
357 meta-analysis. Only the cardiovascular and diabetes section had a sufficient number of studies to be able  
358 to further assess a subset of the condition, for example blood pressure. However, if a meta-analysis were  
359 to be conducted on such a specific subset, it may most appropriate to include all RCTs that have been  
360 conducted on the topic, with no date limitation. This is out of the scope of this potential review, but could  
361 be the topic of future research. If there could be a consensus of future research to all collect data on a  
362 specific outcome, a meta-analysis could be conducted to look at pharmaceutical care overall.

363 Currently there is a gap in current knowledge regarding the long term effects of pharmaceutical care  
364 interventions. Cooper and colleagues reported that patients show improvements in the first six months of  
365 interventions due to the psychological effects of being monitored, and this often drops off thereafter (91).  
366 The most frequently used follow up time in our review was six months, and one study did note that the  
367 beneficial effects seen dissipated when the intervention ceased (42). Future intervention studies with  
368 pharmaceutical care should bear this in mind. One of the studies in our review did have a sham  
369 intervention condition, and this study did find significant differences after pharmaceutical care (30).

370 Possibly future studies should aim to have a sham arm to the trial, therefore the pharmaceutical care  
371 aspect of the intervention can be differentiated in the methodology (19). In addition long term  
372 consequences of these interventions should be examined.

373  
374 The present study has certain limitations. The study is limited to the English language literature and  
375 studies in other languages were not included. Only original research RCTs are included in the review;  
376 secondary studies were excluded. This study also included the specific outcomes of hospitalizations,  
377 mortality and surrogate clinical outcomes, therefore not incorporating HRQOL score, patient satisfaction  
378 or adherence scores, future studies could focus on these aspects to evaluate the full spectrum of  
379 pharmaceutical care effects on patients.

#### 380 **Conclusion**

381 RCTs conducted to evaluate pharmaceutical care appear to be effective in improving patient short-term  
382 outcomes for a number of conditions including diabetes and cardiovascular conditions, however, other  
383 conditions such as depression are less well researched. Future research should attempt to evaluate  
384 whether these effects persist and the long-term clinical outcomes.

#### 385 **Authors Contributions**

386 ZB conceived the study. RK and LC conducted the literature searches and extracted data with input from  
387 ZB. All authors were responsible for data interpretation. RK LC and ZB drafted the manuscript and all  
388 other authors revised and approved the manuscript.

#### 389 **Conflicts of interest**

390 There were no conflicts of interest.

391 **References**

- 392 1. Beard JR, Bloom DE. Towards a comprehensive public health response to population ageing.  
393 *Lancet*. 2015;385(9968):658-61.
- 394 2. Morris CJ, Cantrill JA, Weiss MC. GPs' attitudes to minor ailments. *Family Practice*.  
395 2001;18(6):581-5.
- 396 3. Bodenheimer T, Pham HH. Primary care: Current problems and proposed  
397 solutions. *Health Affairs*. 2010;29(5):799-805.
- 398 4. Evans R, McGrail K, Morgan S, Barer M, Hertzman C. Apocalypse No : population aging and the  
399 future of health care systems. *Social and Economic Dimensions of an Ageing Population*. 2001;Research  
400 paper 59.
- 401 5. Anonymous. Public Health and Aging: Trends in Aging—United States and Worldwide. *JAMA*.  
402 2003;289(11):1371-3.
- 403 6. Cornwall J, Davey JA. Impact of population ageing in New Zealand on the demand for health and  
404 disability support services and workforce implications New Zealand Institute for Research on Ageing  
405 (NZIRA) and the Health Services Research Centre (HSRC), Victoria University of Wellington 2004.
- 406 7. Baqir W, Learoyd T, Sim A, Todd A. Cost analysis of a community pharmacy 'minor ailment  
407 scheme' across three primary care trusts in the North East of England. *Journal of Public Health*.  
408 2011;33(4):551-5.
- 409 8. Bojke C, Gravelle H, Hassell K, Whittington Z. Increasing patient choice in primary care: the  
410 management of minor ailments. *Health Economics*. 2004;13(1):73-86.
- 411 9. Aguiar PM, Balisa-Rocha BJ, Brito GC, Lyra DP. Pharmaceutical care program for elderly patients  
412 with uncontrolled hypertension. *Journal of the American Pharmacists Association*. 2012;52(4):515-8.
- 413 10. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. *Am J Hosp*  
414 *Pharm*. 1990;47(3):533-43.
- 415 11. Martin-Calero M, Machuca M, Murillo M, Cansino J, Gastelurrutia M, Faus M. Structural process  
416 and implementation programs of pharmaceutical care in different countries. *Current Pharmaceutical*  
417 *Design*. 2004;10(31):3969-85.
- 418 12. Cheng Y, Raisch DW, Borrego ME, Gupchup GV. Economic, clinical, and humanistic outcomes  
419 (ECHOs) of pharmaceutical care services for minority patients: A literature review. *Research in Social and*  
420 *Administrative Pharmacy*. 2013;9(3):311-29.
- 421 13. Roughead L, Semple S, Vitry A. The value of pharmacist professional services in the community  
422 setting. A systematic review of the literature. 1990;2002:2002-507.
- 423 14. Barber N. Pharmaceutical care and medicines management-is there a difference? *Pharmacy*  
424 *World & Science*. 2001;23(6):210-1.
- 425 15. Beney J, Bero L, Bond CM. Expanding the roles of outpatient pharmacists: effects on health  
426 services utilisation, costs, and patient outcomes. *The Cochrane Library*. 2000.
- 427 16. Van Mil F. Proving the benefits of pharmaceutical care. *Pharmacy World and Science*.  
428 2004;26:123.
- 429 17. Christensen D, Ferguson M, Garrett D, Bunting B, Malone D, Cranor C. Studying pharmaceutical  
430 care: difficult but necessary. *Journal of the American Pharmacists Association: JAPhA*. 2002;43(5 Suppl  
431 1):S36-7.
- 432 18. McLean WM, MacKeigan LD. When Does Pharmaceutical Care Impact Health Outcomes? A  
433 Comparison of Community Pharmacy—Based Studies of Pharmaceutical Care for Patients with Asthma.  
434 *Annals of Pharmacotherapy*. 2005;39(4):625-31.
- 435 19. Aguiar PM, Balisa-Rocha BJ, Brito GD, da Silva WB, Lyra DP, et al. Pharmaceutical care in  
436 hypertensive patients: A systematic literature review. *Res Social Adm Pharm*. 2012;8(5):383-96.

- 437 20. Morgado MP, Morgado SR, Mendes LC, Pereira LJ, Castelo-Branco M. Pharmacist interventions  
438 to enhance blood pressure control and adherence to antihypertensive therapy: Review and meta-  
439 analysis. *Am J Health-Syst Pharm*. 2011;68(3):241-53.
- 440 21. Stemer G, Lemmens-Gruber R. Clinical pharmacy activities in chronic kidney disease and end-  
441 stage renal disease patients: A systematic literature review. *BMC Nephrology*. 2011;12 (1) (no  
442 pagination)(35).
- 443 22. van Mil JF, Schulz M. A review of pharmaceutical care in community pharmacy in Europe.  
444 *Harvard Health Policy Review*. 2006;7(1):155-68.
- 445 23. Roughead E, Semple S, Vitry A. Pharmaceutical care services: a systematic review of published  
446 studies, 1990 to 2003, examining effectiveness in improving patient outcomes. *International Journal of*  
447 *Pharmacy Practice*. 2005;13(1):53-70.
- 448 24. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the  
449 quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials*. 1996;17(1):1-12.
- 450 25. Salazar A, Amariles P, Hincapie JA, Gonzalez JS, Benjumea D, Faus Dader MJ. Effectiveness of the  
451 Dader Method for pharmaceutical care in patients with bipolar I disorder: EMDADER-TAB: Randomized  
452 controlled trial. *Int J Clin Pharm*. 2016;38 (6):475-6.
- 453 26. Agency for Healthcare Research and Quality (AHRQ). Making health care safer: a critical  
454 analysis of patient safety practices. [Internet]: Rockville: US Department of Health and Human Services;  
455 2001 [
- 456 27. Amariles P, Sabater-Hernandez D, Garcia-Jimenez E, Rodriguez-Chamorro MA, Prats-Mas R,  
457 Marin-Magan F, et al. Effectiveness of Dader Method for pharmaceutical care on control of blood  
458 pressure and total cholesterol in outpatients with cardiovascular disease or cardiovascular risk:  
459 EMDADER-CV randomized controlled trial. *J Manage Care Pharm*. 2012;18(4):311-23.
- 460 28. Bell SP, Schnipper JL, Goggins K, Bian A, Shintani A, Roumie CL, et al. Effect of Pharmacist  
461 Counseling Intervention on Health Care Utilization Following Hospital Discharge: A Randomized Control  
462 Trial. *J Gen Intern Med*. 2016;31(5):470-7.
- 463 29. Community Pharmacy Medicines Management Project Evaluation T. The MEDMAN study: a  
464 randomized controlled trial of community pharmacy-led medicines management for patients with  
465 coronary heart disease. *Fam Pract*. 2007;24(2):189-200.
- 466 30. de Castro MS, Fuchs FD, Santos MC, Maximiliano P, Gus M, Moreira LB, et al. Pharmaceutical  
467 care program for patients with uncontrolled hypertension. Report of a double-blind clinical trial with  
468 ambulatory blood pressure monitoring. *Am J Hypertens*. 2006;19(5):528-33.
- 469 31. Firmino PYM, Vasconcelos TO, Ferreira CC, Moreira LM, Romero NR, Dias LA, et al.  
470 Cardiovascular risk rate in hypertensive patients attended in primary health care units: The influence of  
471 pharmaceutical care. *Brazilian Journal of Pharmaceutical Sciences*. 2015;51(3):617-28.
- 472 32. Firmino PY, Vasconcelos TO, Ferreira CC, Moreira LM, Fonteles MM, et al. Cardiovascular risk  
473 rate in hypertensive patients attended in primary health care units: the influence of pharmaceutical  
474 care. *Brazilian Journal of Pharmaceutical Sciences*. 2015;51(3):617-27.
- 475 33. Garcia BH, Giverhaug T, Hogli JU, Skjold F, Smabrekke L. A pharmacist-led follow-up program for  
476 patients with established coronary heart disease in North Norway - A randomized controlled trial.  
477 *Pharmacy Practice*. 2015;13(2):1-10.
- 478 34. Green BB, Cook AJ, Ralston JD, Fishman PA, Catz SL, Carlson J, et al. Effectiveness of home blood  
479 pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized  
480 controlled trial.[Erratum appears in *JAMA*. 2009 Nov 11;302(18):1972]. *Jama*. 2008;299(24):2857-67.
- 481 35. Hammad EA, Yasein N, Tahaineh L, Albsoul-Younes AM. A randomized controlled trial to assess  
482 pharmacist-physician collaborative practice in the management of metabolic syndrome in a university  
483 medical clinic in Jordan. *J Manage Care Pharm*. 2011;17(4):295-303.

- 484 36. Holland R, Brooksby L, Lenaghan E, Ashton K, Harvey I, et al. Effectiveness of visits from  
485 community pharmacists for patients with heart failure: HeartMed randomised controlled trial. *Br Med J*.  
486 2007;334(7603):1098-101.
- 487 37. Lalonde L, Martineau J, Blais N, Montigny M, Ginsberg J, Fournier M, et al. Is long-term  
488 pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial. *Am*  
489 *Heart J*. 2008;156(1):148-54.
- 490 38. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and  
491 persistence, blood pressure, and low-density lipoprotein cholesterol: A randomized controlled trial.  
492 *Journal of the American Medical Association*. 2006;296(21):2563-71.
- 493 39. Lee VW, Fan CS, Li AW, Chau AC. Clinical impact of a pharmacist-physician co-managed  
494 programme on hyperlipidaemia management in Hong Kong. *J Clin Pharm Ther*. 2009;34(4):407-14.
- 495 40. Ma Y, Ockene IS, Rosal MC, Merriam PA, Ockene JK, Gandhi PJ. Randomized trial of a  
496 pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients  
497 with coronary heart disease. *Cholesterol*. 2010;2010 (no pagination)(383281).
- 498 41. Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance  
499 hypertension control: A randomised controlled trial. *Int J Clin Pharm*. 2011;33(1):132-40.
- 500 42. Murray MD, Young J, Hoke S, Tu W, Weiner M, Morrow D, et al. Pharmacist intervention to  
501 improve medication adherence in heart failure: A randomized trial. *Ann Intern Med*. 2007;146(10):714-  
502 25.
- 503 43. Paulos CP, Nygren CE, Celedon C, Carcamo CA. Impact of a pharmaceutical care program in a  
504 community pharmacy on patients with dyslipidemia. *Ann Pharmacother*. 2005;39(5):939-43.
- 505 44. Peterson GM, Fitzmaurice KD, Naunton M, Vial JH, Krum H, et al. Impact of pharmacist-  
506 conducted home visits on the outcomes of lipid-lowering drug therapy. *J Clin Pharm Ther*.  
507 2004;29(1):23-30.
- 508 45. Plaster CP, Melo DT, Boldt V, Cassaro KOS, Lessa FCR, Boechat GAP, et al. Reduction of  
509 cardiovascular risk in patients with metabolic syndrome in a community health center after a  
510 pharmaceutical care program of pharmacotherapy follow-up. *Brazilian Journal of Pharmaceutical*  
511 *Sciences*. 2012;48(3):435-46.
- 512 46. Qudah B, Albsoul-Younes A, Alawa E, Mehvar N. Role of clinical pharmacist in the management  
513 of blood pressure in dialysis patients. *Int J Clin Pharm*. 2016;38(4):931-40.
- 514 47. Sadik A, Yousif M, McElnay JC. Pharmaceutical care of patients with heart failure. *Br J Clin*  
515 *Pharmacol*. 2005;60(2):183-93.
- 516 48. Sookaneknun P, Richards RM, Sanguanserm Sri J, Teerasut C. Pharmacist involvement in primary  
517 care improves hypertensive patient clinical outcomes. *Ann Pharmacother*. 2004;38(12):2023-8.
- 518 49. Villa LA, Von Chrismar AM, Oyarzun C, Eujenin P, Quezada M, et al. Pharmaceutical Care  
519 Program for Dyslipidemic Patients at Three Primary Health Care Centers: Impacts and Outcomes. *ACTA*  
520 *FARM BONAER*. 2009;28(3):415-20,21-65.
- 521 50. Wang J, Wu J, Yang J, Zhuang Y, Chen J, Qian W, et al. Effects of pharmaceutical care  
522 interventions on blood pressure and medication adherence of patients with primary hypertension in  
523 China. *Clinical Research and Regulatory Affairs*. 2011;28(1):1-6.
- 524 51. Zhao P, Wang C, Qin L, Yuan M, Xiao Q, Guo Y, et al. Effect of clinical pharmacist's  
525 pharmaceutical care intervention to control hypertensive outpatients in China. *African Journal of*  
526 *Pharmacy and Pharmacology*. 2012;6(1):48-56.
- 527 52. Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of  
528 pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus. *Br J Clin Pharmacol*.  
529 2009;67(5):547-57.

- 530 53. Chen JH, Ou HT, Lin TC, Lai ECC, Yang Kao YH. Pharmaceutical care of elderly patients with  
531 poorly controlled type 2 diabetes mellitus: a randomized controlled trial. *Int J Clin Pharm*. 2016;38(1):88-  
532 95.
- 533 54. Chung WW, Chua SS, Lai PS, Chan SP. Effects of a pharmaceutical care model on medication  
534 adherence and glycemic control of people with type 2 diabetes. *Patient Prefer Adherence*. 2014;8:1185-  
535 94.
- 536 55. Clifford RM, Batty KT, Davis WA, Davis TM. Effect of a pharmaceutical care program on vascular  
537 risk factors in type 2 diabetes - The Fremantle Diabetes study. *Diabetes Care*. 2005;28(4):771-6.
- 538 56. Doucette WR, Witry MJ, Farris KB, McDonough RP. Community Pharmacist-Provided Extended  
539 Diabetes Care. *Ann Pharmacother*. 2009;43(5):882-9.
- 540 57. Elnour AA, El Mugammar IT, Jaber T, Revel T, McElnay JC. Pharmaceutical care of patients with  
541 gestational diabetes mellitus. *J Eval Clin Pract*. 2008;14(1):131-40.
- 542 58. Jameson JP, Baty PJ. Pharmacist collaborative management of poorly controlled diabetes  
543 mellitus: a randomized controlled trial. *Am J Manag Care*. 2010;16(4):250-5.
- 544 59. Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. Randomized controlled trial of clinical  
545 pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. *J*  
546 *Manage Care Pharm*. 2012;18(7):516-26.
- 547 60. Mahwi TO, Obied KA. Role of the pharmaceutical care in the management of patients with type  
548 2 diabetes mellitus. *International Journal of Pharmaceutical Sciences and Research*. 2013;4(4):1363-9.
- 549 61. McLean DL, McAlister FA, Johnson JA, King KM, Makowsky MJ, Jones CA, et al. A randomized  
550 trial of the effect of community pharmacist and nurse care on improving blood pressure management in  
551 patients with diabetes mellitus: Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension  
552 (SCRIP-HTN). *Arch Intern Med*. 2008;168(21):2355-61.
- 553 62. Mourao AOM, Ferreira WR, Martins MAP, Reis AMM, Carrillo MRG, Guimaraes AG, et al.  
554 Pharmaceutical care program for type 2 diabetes patients in Brazil: A randomised controlled trial. *Int J*  
555 *Clin Pharm*. 2013;35(1):79-86.
- 556 63. Obreli-Neto PR, Guidoni CM, De Oliveira Baldoni A, Pilger D, Cruciol-Souza JM, Gaeti-Franco WP,  
557 et al. Effect of a 36-month pharmaceutical care program on pharmacotherapy adherence in elderly  
558 diabetic and hypertensive patients. *Int J Clin Pharm*. 2011;33(4):642-9.
- 559 64. Odegard PS, Goo A, Hummel J, Williams KL, Gray SL. Caring for poorly controlled diabetes  
560 mellitus: a randomized pharmacist intervention. *Ann Pharmacother*. 2005;39(3):433-40.
- 561 65. Wishah RA, Al-Khawaldeh OA, Albsoul AM. Impact of pharmaceutical care interventions on  
562 glycemic control and other health-related clinical outcomes in patients with type 2 diabetes:  
563 Randomized controlled trial. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2014.
- 564 66. Xin C, Xia Z, Jiang C, Lin M, Li G. Effect of pharmaceutical care on medication adherence of  
565 patients newly prescribed insulin therapy: A randomized controlled study. *Patient Preference and*  
566 *Adherence*. 2015;9:797-802.
- 567 67. Marques LA, Galduroz JC, Fernandes MR, Oliveira CC, Noto AR, et al. Assessment of the  
568 Effectiveness of Pharmacotherapy Follow-up in Patients Treated for Depression. *J Manage Care Pharm*.  
569 2013;19(3):218-27.
- 570 68. Rubio-Valera M, March Pujol M, Fernandez A, Penarrubia-Maria MT, Trave P, Lopez del Hoyo Y,  
571 et al. Evaluation of a pharmacist intervention on patients initiating pharmacological treatment for  
572 depression: A randomized controlled superiority trial. *Eur Neuropsychopharmacol*. 2013;23(9):1057-66.
- 573 69. Crotty M, Rowett D, Spurling L, Giles LC, Phillips PA. Does the addition of a pharmacist transition  
574 coordinator improve evidence-based medication management and health outcomes in older adults  
575 moving from the hospital to a long-term care facility? Results of a randomized, controlled trial. *American*  
576 *Journal Geriatric Pharmacotherapy*. 2004;2(4):257-64.

- 577 70. Holland R, Lenaghan E, Harvey I, Smith R, Hand C, et al. Does home based medication review  
578 keep older people out of hospital? The HOMER randomised controlled trial. *Br Med J*.  
579 2005;330(7486):293-5.
- 580 71. Lenaghan E, Holland R, Brooks A. Home-based medication review in a high risk elderly  
581 population in primary care--the POLYMED randomised controlled trial. *Age Ageing*. 2007;36(3):292-7.
- 582 72. Lenander C, Elfsson B, Danielsson B, Midlov P, Hasselstrom J. Effects of a pharmacist-led  
583 structured medication review in primary care on drug-related problems and hospital admission rates: a  
584 randomized controlled trial. *Scand J Prim Health Care*. 2014;32(4):180-6.
- 585 73. Olesen C, Harbig P, Buus KM, Barat I, Damsgaard EM. Impact of pharmaceutical care on  
586 adherence, hospitalisations and mortality in elderly patients. *Int J Clin Pharm*. 2014;36(1):163-71.
- 587 74. Spinewine A, Swine C, Dhillon S, Lambert P, Nachege JB, Wilmotte L, et al. Effect of a  
588 collaborative approach on the quality of prescribing for geriatric inpatients: a randomized, controlled  
589 trial. *J Am Geriatr Soc*. 2007;55(5):658-65.
- 590 75. Abdelhamid E, Awad A, Gismallah A. Evaluation of a hospital pharmacy-based pharmaceutical  
591 care services for asthma patients. *Pharmacy Practice*. 2008;6(1):25-32.
- 592 76. Tommelein E, Mehuys E, Van Hees T, Adriaens E, Van Bortel L, Christiaens T, et al. Effectiveness  
593 of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): A  
594 randomized controlled trial. *Br J Clin Pharmacol*. 2014;77(5):756-66.
- 595 77. Wei L, Yang X, Li J, Liu L, Luo H, Zheng Z, et al. Effect of pharmaceutical care on medication  
596 adherence and hospital admission in patients with chronic obstructive pulmonary disease (COPD): A  
597 randomized controlled study. *Journal of Thoracic Disease*. 2014;6(6):656-62.
- 598 78. Basheti IA, Tadros OKI, Aburuz S. Value of a Community-Based Medication Management Review  
599 Service in Jordan: A Prospective Randomized Controlled Study. *Pharmacotherapy*. 2016;36(10):1075-86.
- 600 79. Lai PS, Chua SS, Chew YY, Chan SP. Effects of pharmaceutical care on adherence and persistence  
601 to bisphosphonates in postmenopausal osteoporotic women. *J Clin Pharm Ther*. 2011;36(5):557-67.
- 602 80. Losada-Camacho M, Guerrero-Pabon MF, Garcia-Delgado P, Martinez-Martinez F. Impact of a  
603 pharmaceutical care programme on health-related quality of life among women with epilepsy: A  
604 randomised controlled trial (IPHIWWE study). *Health and Quality of Life Outcomes*. 2014;12 (1) (no  
605 pagination)(162).
- 606 81. Wu JY, Leung WY, Chang S, Lee B, Zee B, Tong PC, et al. Effectiveness of telephone counselling  
607 by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial.  
608 *Bmj*. 2006;333(7567):522.
- 609 82. Obreli-Neto PR, Marusic S, Guidoni CM, Baldoni AdO, Renovato RD, Pilger D, et al. Economic  
610 evaluation of a pharmaceutical care program for elderly diabetic and hypertensive patients in primary  
611 health care: a 36-month randomized controlled clinical trial. *J Manag Care Spec Pharm*. 2015;21(1):66-  
612 75.
- 613 83. Magalhaes Mourao AO, Ferreira WR, Parreiras Martins MA, Moreira Reis AM, Gaede Carrillo  
614 MR, Guimaraes AG, et al. Pharmaceutical care program for type 2 diabetes patients in Brazil: a  
615 randomised controlled trial. *International Journal of Clinical Pharmacy*. 2013;35(1):79-86.
- 616 84. Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of  
617 pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus. *Br J Clin Pharmacol*.  
618 2009;67(5):547-57.
- 619 85. Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with  
620 heart failure: a systematic review of randomized trials. *Arch Intern Med*. 2008;168(7):687-94.
- 621 86. Fornos AJ, Andre's NF, Andre's JC, Guerra MM, A EB. Pharmacotherapy follow-up program in  
622 patients with type-2 diabetes in community pharmacies in Spain. *Pharm World Sci*. 2006;28:65-72.
- 623 87. Balaiah S, Tirupa M, Narayana G, Mohanraj R, Reddy YP. ASSESSMENT OF PHARMACEUTICAL  
624 CARE SERVICES ON HEALTH RELATED QOL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS--A



- 625 PROSPECTIVE INTERVENTIONAL STUDY. *International Journal of Pharmacy and Pharmaceutical Sciences*.  
626 2014;6(7).
- 627 88. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia  
628 with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective  
629 observational study. *Bmj*. 2000;321(7258):405-12.
- 630 89. Cooper JA, Cadogan CA, Patterson SM, Kerse N, Bradley MC, Ryan C, et al. Interventions to  
631 improve the appropriate use of polypharmacy in older people: A Cochrane systematic review. *BMJ*  
632 *Open*. 2015;5 (12) (no pagination)(e009235).
- 633 90. Holland R, Desborough J, Goodyer L, Hall S, Wright D, Loke YK. Does pharmacist-led medication  
634 review help to reduce hospital admissions and deaths in older people? A systematic review and meta-  
635 analysis. *Br J Clin Pharmacol*. 2008;65(3):303-16.
- 636 91. Cooper H, Booth K, Fear S, Gill G. Chronic disease patient education: lessons from meta-  
637 analyses. *Patient Educ Couns*. 2001;44(2):107-17.

638